Selank is a synthetic peptide analog of tuftsin, an immunomodulatory tetrapeptide, extended with additional amino acids for improved stability.
🔬 Studied for: Anxiolytic Research
💊 Also studied for: Nootropic & Cognitive Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
Selank is a synthetic peptide analog of tuftsin, an immunomodulatory tetrapeptide, extended with additional amino acids for improved stability. It was developed in Russia and has been studied there for several decades as both an anxiolytic and nootropic research candidate.
Selank is studied for its effects on the GABAergic and serotonergic systems, and research has also examined its influence on brain-derived neurotrophic factor (BDNF) expression, mechanisms researchers have proposed underlie its studied anxiolytic and cognitive effects.
These are effects Selank has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
A substantial share of the Selank literature, originating largely from Russian research institutions, has examined its effects in animal models of anxiety-like behavior without the sedative profile associated with benzodiazepines.
Selank has also been studied for effects on learning and memory consolidation in animal models, an area of research interest that overlaps with its proposed influence on neurotrophic signaling.
Clinical protocols studied in Russian trials used intranasal administration; no FDA-established human dosage exists in the United States, and research-grade material should be used per applicable laboratory protocols only.
Compound X does not provide dosing recommendations. Selank is sold for laboratory research use only and is not intended for human consumption.
Selank is approved as a prescription anxiolytic in Russia but does not hold FDA approval in the United States, and comprehensive Western clinical trial data is limited. Reported concerns in available research and anecdotal reports are generally mild, including nasal irritation with intranasal administration, though independent, large-scale human safety data remains limited outside Russian trials.
No. Selank is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Anxiolytic Research — A substantial share of the Selank literature, originating largely from Russian research institutions, has examined its effects in animal models of anxiety-like behavior without the sedative profile associated with benzodiazepines.
In the US, UK, Canada and Australia, Selank is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Selank research is indexed on PubMed under search terms such as "Selank tuftsin analog" and "Selank anxiolytic peptide."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.